Clinical Trial

Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease

Study acronym: EMPA-PD
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The main purpose of the study is to determine if empagliflozin can reduce peritoneal glucose absorption in patients with end stage renal diease (ESRD) on peritoneal dialysis. This is a randomized, placebo controlled, acute crossover study of empagliflozin in an anticipated 30 chronic PD patients, with an 8 week "pre post" open label extension in all 30 patients where they will receive empagliflozin daily.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2022-12-22; most recent amendment 2026-05-18.
Status change: Not Yet Recruiting → Recruiting 2023-05-01
Trial Details
NCT Number NCT05671991
Lead Sponsor Yale University
Collaborators: Boehringer Ingelheim
Conditions End Stage Renal Disease on Dialysis
Enrollment 30 participants
Start Date 2023-03-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-22